Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12424)	12/10/1999 10:04:00 PM
From: Bluegreen	Respond to of 17367

FIRST CHINA NOW SPREADING THE WORD TO JAPAN!!!!!!!!!!!!! Look and see how they know about LBP!!!!!!!!!!>>>>>>>>>>>Masui 1999 Nov;48(11):1186-93 [Antimicrobial peptides/proteins--application to the therapy of sepsis]. [Article in Japanese] Sawa T, Kurahashi K Department of Anesthesia, University of California, San Francisco, USA. Many antimicrobial peptides and proteins were discovered recently in various animals. Cecropins are insect-derived antimicrobial peptides which contain 35-39 amino acid residues. Magainins are amphibian-derived antimicrobial peptides with 21-27 amino acid residues. In mammals, defensins, 29-35 amino acid peptides, were identified in the granules of neutrophils and various epithelial cells. In addition, the granules of neutrophils in the mammal have been shown to have several antimicrobial proteins. Among them, bactericidal/permeability increasing protein (BPI) and cationic antimicrobial peptide-18 (CAP 18) have been found to have potent bactericidal activity against gram-negative bacteria and strong lipopolysaccharide-neutralizing function. The recombinant BPIs (recombinant BPI, 23-kDa N-terminal fragment of BPI, and lipopolysaccharide-binding protein-BPI fusion protein) and synthetic peptides derived from C-terminal of CAP 18 are now under investigation for the application to the therapy of sepsis or septic shock.<<<<<<<<<<<<<<

To: aknahow who wrote (12424)	12/11/1999 10:48:00 AM
From: jackie	Respond to of 17367

George, Footnote on article states: <<At the time of publication, Manny Tzavlakis was long shares of MedImmune and XOMA.>> Thanks for link. Jack